Aspirin
Severe
Database
Drug interaction classified as: distribution.
Source: DDInter
Drug reference
Brinzolamide
Topical carbonic anhydrase inhibitor (ophthalmic) · Antiglaucoma Agent
START
1 drop 1% in affected eye(s) twice daily
TYPICAL MAX
1 drop three times daily per eye
STOP IF
Hypersensitivity, severe ocular reaction, or corneal oedema
WATCH
IOP response, corneal status; sulfonamide allergy history
CDSCO approvedSchedule HATC S01EC04
KDIGO 2024 + manufacturer label
- ONSET
- 1h · IOP fall
- PEAK
- 2.5h · peak IOP effect
- t½
- 4.6d · RBC-bound
- DURATION
- 10h · per dose
EXCRETION
Renal — unchanged drug and metabolite
route + CYP
INTERACTIONS
6 major
SEVERE in our sources
PREGNANCY
Limited data; use only if benefit outweighs risk.
FDA category + note
Top interactionssee all 8 →
- AspirinSevereDatabaseDDInter
- Bismuth SubsalicylateSevereDatabaseDDInter
- Choline SalicylateSevereDatabaseDDInter
- DiflunisalSevereDatabaseDDInter
Available in India
6 branded formulations. Look up specific brands in the Drugs workspace.
Mechanism
Inhibits carbonic anhydrase II in the ciliary processes, reducing aqueous humour formation and lowering intraocular pressure.
Indications
Elevated intraocular pressure in ocular hypertensionOpen-angle glaucoma
Dosing
- Adult
- 1 drop of 1% suspension in the affected eye(s) 2–3 times daily.
- Pediatric
- Safety/efficacy not established (limited use).
- Renal adjustment
- Not recommended if CrCl <30 mL/min (systemic CAI accumulation).
- Hepatic adjustment
- Not studied; caution.
- Geriatric
- No specific adjustment.
- Max dose
- 1 drop three times daily per eye
Pharmacokinetics
Onset
IOP reduction within hours
Peak effect
~2–3 h post-instillation
Duration
~8–12 h
Half-life
Long (RBC carbonic anhydrase binding; ~111 days systemic)
Bioavailability
Low systemic (topical)
Protein binding
~60%
Metabolism
Minimal (N-desethyl active metabolite)
Excretion
Renal (unchanged drug and metabolite)
Contraindications
- Hypersensitivity to brinzolamide/sulfonamides
- Severe renal impairment (CrCl <30)
- Hyperchloraemic acidosis
Side effects
Common
Blurred visionBitter/abnormal tasteOcular discomfortDry eyeForeign-body sensation
Serious
- Sulfonamide hypersensitivity (Stevens-Johnson, rare)
- Corneal oedema (endothelial compromise)
- Systemic acid-base disturbance (rare)
Pregnancy & lactation
Pregnancy
Limited data; use only if benefit outweighs risk.
Lactation
Unknown if excreted in human milk; caution.
Drug interactions
Bismuth Subsalicylate
Severe
Database
Clinical effect not specified
Source: DDInter
Choline Salicylate
Severe
Database
Clinical effect not specified
Source: DDInter
Diflunisal
Severe
Database
Drug interaction classified as: distribution
Source: DDInter
Phenyl Salicylate
Severe
Database
Clinical effect not specified
Source: DDInter
Salsalate
Severe
Database
Drug interaction classified as: distribution
Source: DDInter
High Dose Salicylates
Moderate
Database
CAI–salicylate interaction
Avoid combination
Source: Kimi deep-research + Cla
Oral Carbonic Anhydrase Inhibitors
Moderate
Database
Additive systemic CAI effect
Avoid concurrent systemic CAI
Source: Kimi deep-research + Cla
4 additional low-confidence interactions hidden — those rows lack a documented mechanism or management plan in our sources.
Related guidelines
Other Topical carbonic anhydrase inhibitor (ophthalmic) drugs
Ask House about Brinzolamide
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e, BNF·Verified: 2026-05-20 · House clinical team·Cockpit curated: 2026-05-20